AEON Biopharma

United States
Newport Beach, California, United States

Company profile

AEON Biopharma company profile

AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is dedicated to developing novel and proprietary treatment paradigms in order to improve patient outcomes and drive increased value for patients, physicians, and payers.

Business identity

Contact email
[email protected]
Phone number
+1-949-298-2211
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2013-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$42M
Last funding
Post IPO Equity / $22M / 2025-11-13
Last equity funding
Post IPO Equity / $22M
Investors
2
Lead investors
1
Articles
94
Exited on
2023-07-24

Founders and investors

Lead investors

Daewoong Pharmaceutical

Investors

DaewoongDaewoong Pharmaceutical